Events
Upcoming events
10 – 11 May 2022
FutureTox V
FutureTox V: New Technologies to Evaluate Organ-Specific Effects of Drugs and Chemicals will focus on issues of interest to regulatory and investigative toxicologists and discuss new technologies and strategies that are being used to improve, reduce, and/or replace animal testing (3Rs).
30 May – 3 June 2022
Microphysiological Systems World Summit
The MPS (Microphysiological Systems) World Summit in New Orleans will bring together a global audience. This will be a first step in
establishing an international MPS society
Previous events
Catch some of our past events on-demand
Webinar Series 4 Episode 4
From Dose to Circulation – Determination of Drug Oral Bioavailability Using a Gut-Liver Microphysiological System
In this webinar, Dr. Yassen Abbas will discuss how CN-Bio’s gut-liver MPS can be used for in vitro determination of oral bioavailability. This application has been validated with drugs with known human bioavailability and with a mathematical model developed to enable prediction of oral bioavailability in silico.
Webinar Series 4 Episode 3
Fighting Toxic Chemicals – Evaluating the Safety of Cobinamide as a Neutralizing Agent
This webinar will outline how Boss’ lab used CN Bio’s Toxicity Testing Services to investigate the hepatotoxicity of two cobinamide formulations. Dr. Boss will discuss the results of the research, study and how the work informed which formulations of cobinamide could be safe for humans.
Webinar Series 4 Episode 2
Human Liver Microphysiological System for Studying Acute and Chronic Drug-Induced Liver Toxicity
In this webinar, CN Bio Senior Scientist Dr. Ovidiu Novac will discuss how a human liver microphysiological system (MPS), or Liver-on-a-chip, can be used to understand the causality and mechanistic aspects of drug-induced liver injury (DILI).
Webinar Series 4 Episode 1
Liver-on-Chip and In Silico Modeling for Quantitative Drug Metabolism Studies
This webinar will examine the benefits of combining LOAC with in silico modeling to explore clinical PK predictions of specific reference drugs, including investigations into the intrinsic clearance determinations for high metabolically stable compounds and the quantitation of fractions metabolized by specific enzymes.
Webinar Series 3 Episode 4
Bringing Life to PK Profiles
In Vivo-Relevance From an In Vitro Environment. In this webinar, we will introduce a new MPS platform designed to address these challenges: the PhysioMimix™ PK – a novel microformulator developed by CN Bio.
Webinar Series 3 Episode 3
Formulating a New Approach to Pharmacokinetics and Cell State Control
Understand the biological implications of sequential batch feeding of cells in conventional in vitro experiments.
Webinar Series 3 Episode 2
Pathologically Scarred by Fibrosis:
How To Model and Quantify Human NASH in a Microphysiological System. Non-alcoholic steatohepatitis (NASH) is a widespread disease affecting up to ~12% of the US population – characterized by lipid accumulation in hepatocytes, infiltration of immune cells and fibrosis of the liver. Replicating liver fibrosis is a key element in any in vitro NASH model, however, it is normally poorly assessed, unquantifiable and has a limited dynamic range.
Webinar Series 3 Episode 1
Towards a Body-on-a-Chip:
The Value of Multi-Organ MPS for Human-Relevant Drug Assessment. Join Dr Tomasz Kostrzewski, Director of Biology at CN Bio for a brand new webinar exploring how single and multi-organ MPS can be incorporated into your drug discovery and development workflows to increase translation of pre-clinical assays.
Webinar Series 2 Episode 4
Engineering Mucosal Barriers
From Organoids to Organs-on-Chips with Professor Linda Griffith, S.E.T.I. Professor of Biological and Mechanical Engineering Research
Director of the Center for Gynepathology Research at MIT
Webinar Series 2 Episode 3
A Microphysiological Model of Metastatic Progression
Using systems to model metastatic progression. Join Dr Amanda Clark, Research Assistant Professor at University of Pittsburgh.
Webinar Series 2 Episode 2
Testing on Humans
How to Predict Hepatotoxicity and Drug Clearance Ahead of Clinical Trials Using Liver-on-a-Chip. Join Dr Tomasz Kostrzewski, Director of Biology at CN Bio
Webinar Series 2 Episode 1
The Rhythm of Life
Using Microfluidics To Mimic Blood Flow in Single- and Multi-Organ-on-a-Chip Models. Join Dr Graham Broder, Associate Director Engineering and Alysha Bray, Scientist at CN Bio.
Webinar Series 1 Episode 4
A Regulators Viewpoint
Establishing Strategies To Evaluate Microphysiological Systems for Drug Development. Join Dr Alexandre Ribeiro, Staff Fellow (Biological Scientist) at the FDA.
Webinar Series 1 Episode 3
Go with the Flow
Application of Microfluidic 3D Liver Chip Models To Genotoxicity Testing. Join Dr Renato Cardoso, Scientific Director of Genetic Toxicology and Dr Thalita Zanoni, Senior Research Scientist at Charles River Laboratories (Montreal – Canada)
Webinar Series 1 Episode 2
The Scars of Fat
The Transability of 3D NASH Microtissues To Model Human/murine NASH. Join Dr Michele Vacca, Clinical Research Associate Institute of Metabolic Science, TVP Lab at University of Cambridge
Webinar Series 1 Episode 1
An Introduction to Organ-On-a-Chip
The Future of Pre-clinical Drug Research. Join Vaish Manoharan, Account Manager at CN Bio.
Human organ
mimics
Powerful new
data
Translatable
results
COMPANY HEAD OFFICE INFORMATION:
332 Cambridge Science Park
Milton Road
Cambridge
CB4 0WN
+44 (0) 1223 737941
enquiries@cn-bio.com
FOR PRODUCT, SERVICES AND MARKETING ENQUIRIES:
+44 (0) 1223 737941
enquiries@cn-bio.com
CN BIO INNOVATIONS LIMITED REGISTERED OFFICE:
30 Upper High Street, Thame,
Oxfordshire, OX9 3EZ.
Registered No. 06517359.
VAT No. 978184563